anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Expose Contradiction

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 14,162
Current window 10,291-10,320
Pages 473
Rows per page 30
Slide function: Expose Contradictionclear collectionreset all
18 30 60

Slide function

10,291-10,320 of 14,162

filter-aware
288
The slide uses direct quotes from a KOL to build a case against the safety profile of the drug Vykat, specifically highlighting the risk of electrolyte depletion when combined with diuretics.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
289
Uses Q&A format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
290
The slide uses a Q&A format to highlight allegations of 'artificial enrollment' and data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
291
Uses direct quotes from a trial investigator to undermine the validity of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
294
The slide uses direct quotes from a KOL to undermine the company's narrative of drug efficacy and market adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
295
The slide uses a Q&A transcript format to highlight negative sentiment from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
296
The slide uses a Q&A transcript format to provide primary source evidence of a product flaw.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
298
The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
302
The slide uses a Q&A format to highlight potential misconduct by the company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
303
The slide uses a Q&A format to highlight alleged unethical behavior by Soleno regarding academic integrity and investigator relations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
304
The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
305
The slide uses direct quotes from a trial investigator to undermine the drug's market potential and clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
306
The slide uses a Q&A format to present qualitative evidence from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
307
The slide uses a Q&A format to highlight the investigator's skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
308
The slide uses direct quotes from a trial investigator to undermine the validity of clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
309
The slide uses a Q&A format to frame the investigator's critique of the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
312
The slide uses a direct quote from an endocrinologist to cast doubt on the company's clinical data integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
313
The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
318
The slide uses a 'quote-as-evidence' structure to undermine the clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit